Thermo Fisher Scientific Overview
Valuation check: TMO's ROE is 13.24%, below the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow13.24%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Thermo Fisher Scientific (TMO) currently reports a ROE of 13.24%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Thermo Fisher Scientific's ROE history and peer comparisons.
Thermo Fisher Scientific's ROE of 13.24% is lower than the Healthcare sector average of 20.77%. That is roughly 36.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Thermo Fisher Scientific's current 13.24% should be judged against Healthcare norms (sector average: 20.77%) and against TMO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 13.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Thermo Fisher Scientific, and consider following TMO for alerts when major investors trade the stock.
Thermo Fisher Scientific is classified in the Healthcare sector. On ROE, it currently shows 13.24% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TMO with unrelated industries.
